Impact of Pre-transplant Immune Checkpoint Inhibitor Use on Post-transplant Outcomes in HCC: A Systematic Review and Individual Patient Data Meta-analysis

Background & Aims: Treatment with immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) prior to liver transplantation (LT) has been reported; however, ICIs may elevate the risk of allograft rejection and impact other clinical outcomes. This study aims to summarize the impact of ICI use on post-LT outcomes.

Methods: In this individual patient data meta-analysis, we searched databases to identify HCC cases treated with ICIs before LT, detailing allograft rejection, HCC recurrence, and overall survival. We performed Cox regression analysis to identify risk factors for allograft rejection.

Results: Among 91 eligible patients, with a median (IQR) follow-up of 690.0 (654.5) days, there were 24 (26.4%) allograft rejections, 9 (9.9%) HCC recurrences, and 9 (9.9%) deaths. Age (adjusted hazard ratio [aHR] per 10 years 0.72, 95% CI 0.53-0.99, p = 0.044) and ICI washout time (aHR per 1 week 0.92, 95% CI 0.86-0.99, p = 0.022) were associated with allograft rejection. The median (IQR) washout period for patients with ≤20% probability of allograft rejection was 94 (196) days. Overall survival did not differ between cases with and without allograft rejection (log-rank test, p = 0.2). Individuals with HCC recurrence had fewer median (IQR) ICI cycles than those without recurrence (4.0 [1.8] vs. 8.0 [9.0]; p = 0.025). The proportion of patients within Milan post-ICI was lower for those with recurrence vs. without (16.7% vs. 65.3%, p = 0.032).

Conclusion: Patients have acceptable post-LT outcomes after ICI therapy. Age and ICI washout length relate to the allograft rejection risk, and a 3-month washout may reduce it to that of patients without ICI exposure. Number of ICI cycles and tumor burden may affect recurrence risk. Large prospective studies are necessary to confirm these associations.

Impact And Implications: This systematic review and individual patient data meta-analysis of 91 patients with hepatocellular carcinoma and immune checkpoint inhibitor use prior to liver transplantation suggest acceptable overall post-transplant outcomes. Older age and longer immune checkpoint inhibitor washout period have a significant inverse association with the risk of allograft rejection. A 3-month washout may reduce it to that of patients without immune checkpoint inhibitor exposure. Additionally, a higher number of immune checkpoint inhibitor cycles and tumor burden within Milan criteria at the completion of immunotherapy may predict a decreased risk of hepatocellular carcinoma recurrence, but this observation requires further validation in larger prospective studies.

Citing Articles

Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma.

ODonnell C, Majeed U, Rutenberg M, Croome K, Poruk K, Toskich B Curr Oncol. 2025; 32(2).

PMID: 39996882 PMC: 11854535. DOI: 10.3390/curroncol32020082.

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.

Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V JHEP Rep. 2025; 7(2):101246.

PMID: 39911942 PMC: 11794155. DOI: 10.1016/j.jhepr.2024.101246.

Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.

Yue Q, Li X, Wan X, Lin X, Li Y, Zhang M Cancer Med. 2025; 14(1):e70570.

PMID: 39778021 PMC: 11705445. DOI: 10.1002/cam4.70570.

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.

Marzi L, Mega A, Turri C, Gitto S, Ferro F, Spizzo G Int J Mol Sci. 2024; 25(21).

PMID: 39519230 PMC: 11547112. DOI: 10.3390/ijms252111676.

New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.

Mauro E, Rodriguez-Peralvarez M, DAlessio A, Crespo G, Pinero F, De Martin E Liver Int. 2024; 45(4):e16142.

PMID: 39494583 PMC: 11891387. DOI: 10.1111/liv.16142.

References

Nordness M, Hamel S, Godfrey C, Shi C, Johnson D, Goff L . Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. Am J Transplant. 2019; 20(3):879-883. PMC: 10176099. DOI: 10.1111/ajt.15617. View

Sogbe M, Lopez-Guerra D, Blanco-Fernandez G, Sangro B, Narvaez-Rodriguez I . Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: The Importance of a Washout Period. Transplantation. 2021; 105(12):e398-e400. DOI: 10.1097/TP.0000000000003855. View

Shi X, Mancham S, Hansen B, de Knegt R, De Jonge J, van der Laan L . Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. J Hepatol. 2016; 64(6):1274-82. DOI: 10.1016/j.jhep.2016.02.034. View

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson D, Trinh V, Zobniw C . Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019; 7(1):106. PMC: 6469201. DOI: 10.1186/s40425-019-0585-1. View

Rudolph M, Shah S, Quillin R, Lemon K, Olowokure O, Latif T . Immune checkpoint inhibitors in liver transplant: a case series. J Gastrointest Oncol. 2023; 14(2):1141-1148. PMC: 10186520. DOI: 10.21037/jgo-22-922. View

Tabrizian P, Florman S, Schwartz M . PD-1 inhibitor as bridge therapy to liver transplantation?. Am J Transplant. 2020; 21(5):1979-1980. DOI: 10.1111/ajt.16448. View

Tabrizian P, Zeitlhoefler M, Hassan A, Marino R . Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy. Curr Opin Organ Transplant. 2024; 29(2):144-154. DOI: 10.1097/MOT.0000000000001133. View

Gorji L, Brown Z, Pawlik T . Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies. Surg Oncol. 2023; 52:102031. DOI: 10.1016/j.suronc.2023.102031. View

Wang T, Chen Z, Liu Y, Jia Y, Ju W, Chen M . Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss. Liver Transpl. 2023; 29(6):598-606. PMC: 10174104. DOI: 10.1097/LVT.0000000000000083. View

10.

Simoes C, Thung S, Fiel M, Sung M, Schwartz M, Ward S . Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol. 2020; 34(4):823-833. DOI: 10.1038/s41379-020-00679-5. View

11.

Lucas A, Lewis A, Kasi P, Toskich B, Paz-Fumagalli R . Abscopal downstaging of intermediate stage hepatocellular via combination cryoablation and immunotherapy with complete pathologic response. Radiol Case Rep. 2024; 19(3):910-914. PMC: 10770505. DOI: 10.1016/j.radcr.2023.11.062. View

12.

Giudicelli H, Roux C, Monsel A, Conti F, Scatton O, Allaire M . Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation. Clin Res Hepatol Gastroenterol. 2023; 47(7):102167. DOI: 10.1016/j.clinre.2023.102167. View

13.

Schwacha-Eipper B, Minciuna I, Banz V, Dufour J . Immunotherapy as a Downstaging Therapy for Liver Transplantation. Hepatology. 2020; 72(4):1488-1490. DOI: 10.1002/hep.31234. View

14.

Yin J, Wen M, Cheng J, Hu L, Yang L, Chang X . A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. Front Med (Lausanne). 2022; 9:712466. PMC: 8899006. DOI: 10.3389/fmed.2022.712466. View

15.

Lo C, Mertz D, Loeb M . Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014; 14:45. PMC: 4021422. DOI: 10.1186/1471-2288-14-45. View

16.

Xin H, Zhang C, Ding Z, Zhang M, Ding G, Li N . TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports. Clin Res Hepatol Gastroenterol. 2021; 46(1):101777. DOI: 10.1016/j.clinre.2021.101777. View

17.

Gao Q, Anwar I, Abraham N, Barbas A . Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel). 2021; 13(24). PMC: 8699137. DOI: 10.3390/cancers13246307. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Liu M, Lizaola-Mayo B, Jayasekera C, Mathur A, Katariya N, Aqel B . Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant. J Gastrointest Cancer. 2024; 55(2):969-974. DOI: 10.1007/s12029-024-01040-8. View

20.

Tran N, Munoz S, Thompson S, Hallemeier C, Bruix J . Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology. 2022; 76(4):1203-1218. DOI: 10.1002/hep.32613. View